Bovine viral diarrhea virus type 1 - and type 2-specific bovine T lymphocyte - Subset responses following modified-live virus vaccination

Kristina Ripplinger, Mark Quade, Brett Terhaar, James Roth, Janice Endsley

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Expression of CD25 (interleukin-2 receptor a chain) was used to monitor antigen-specific activation of T lymphocyte subsets (CD4+, CD8 +, and gd T cells) from cattle immunized with modified-live virus (MLV) bovine viral diarrhea virus (BVDV) vaccines. Two groups of 15 animals each were vaccinated with one dose of either BVDV genotype 1 (BVDV-1) or BVDV-1 and BVDV genotype 2 (BVDV-1/2). Six animals negative for both BVDV antibody and BVDV virus were used as negative controls. Three animals vaccinated 7 and 5 weeks before the start of the experiment with MLV BVDV-1 vaccine served as positive controls. Blood samples were taken from the negative control group, the positive control group, and the BVDV-1/2 group 0, 21, 35, 60, and 90 days after vaccination. Blood samples were taken from the BVDV-1 group 0, 21, and 90 days after vaccination. Isolated peripheral blood lymphocytes from immunized and control animals were incubated for 5 days with and without BVDV-1 or BVDV-2. Compared with nonvaccinated animals, a significant (P < .05) increase in expression of CD25 by CD4+ (60 days), CD8+, and gd T (35 to 90 days) lymphocytes from the group given BVDV-1/2 was detected following in vitro exposure to BVDV-1 or BVDV-2 after vaccination. The CD8+ and gd T cells from the group vaccinated with BVDV-1 had significantly (P < .05) increased expression of CD25 compared with nonvaccinates following postvaccination exposure to in vitro BVDV-1 but not to BVDV-2. There was no significant difference between the two vaccinated groups in CD25 expression on any of the T cell subsets in response to BVDV-1 or BVDV-2 exposure. A single administration of MLV BVDV vaccine may be more effective at stimulating CD8+ and gd T cell"specific immune responses to the homologous genotype than to the heterologous genotype.

Original languageEnglish (US)
JournalVeterinary Therapeutics
Volume3
Issue number4
StatePublished - 2002
Externally publishedYes

Fingerprint

Bovine viral diarrhea virus 2
Bovine viral diarrhea virus 1
T-Lymphocyte Subsets
Vaccination
T-lymphocytes
vaccination
Viruses
Bovine viral diarrhea virus
viruses
cattle
Bovine Viral Diarrhea Viruses
Genotype
genotype
Vaccines
animals
vaccines
T-Lymphocytes
blood
lymphocytes
Lymphocytes

ASJC Scopus subject areas

  • veterinary(all)

Cite this

Bovine viral diarrhea virus type 1 - and type 2-specific bovine T lymphocyte - Subset responses following modified-live virus vaccination. / Ripplinger, Kristina; Quade, Mark; Terhaar, Brett; Roth, James; Endsley, Janice.

In: Veterinary Therapeutics, Vol. 3, No. 4, 2002.

Research output: Contribution to journalArticle

@article{169b2cc739304e9b892851bcbaa858d9,
title = "Bovine viral diarrhea virus type 1 - and type 2-specific bovine T lymphocyte - Subset responses following modified-live virus vaccination",
abstract = "Expression of CD25 (interleukin-2 receptor a chain) was used to monitor antigen-specific activation of T lymphocyte subsets (CD4+, CD8 +, and gd T cells) from cattle immunized with modified-live virus (MLV) bovine viral diarrhea virus (BVDV) vaccines. Two groups of 15 animals each were vaccinated with one dose of either BVDV genotype 1 (BVDV-1) or BVDV-1 and BVDV genotype 2 (BVDV-1/2). Six animals negative for both BVDV antibody and BVDV virus were used as negative controls. Three animals vaccinated 7 and 5 weeks before the start of the experiment with MLV BVDV-1 vaccine served as positive controls. Blood samples were taken from the negative control group, the positive control group, and the BVDV-1/2 group 0, 21, 35, 60, and 90 days after vaccination. Blood samples were taken from the BVDV-1 group 0, 21, and 90 days after vaccination. Isolated peripheral blood lymphocytes from immunized and control animals were incubated for 5 days with and without BVDV-1 or BVDV-2. Compared with nonvaccinated animals, a significant (P < .05) increase in expression of CD25 by CD4+ (60 days), CD8+, and gd T (35 to 90 days) lymphocytes from the group given BVDV-1/2 was detected following in vitro exposure to BVDV-1 or BVDV-2 after vaccination. The CD8+ and gd T cells from the group vaccinated with BVDV-1 had significantly (P < .05) increased expression of CD25 compared with nonvaccinates following postvaccination exposure to in vitro BVDV-1 but not to BVDV-2. There was no significant difference between the two vaccinated groups in CD25 expression on any of the T cell subsets in response to BVDV-1 or BVDV-2 exposure. A single administration of MLV BVDV vaccine may be more effective at stimulating CD8+ and gd T cell{"}specific immune responses to the homologous genotype than to the heterologous genotype.",
author = "Kristina Ripplinger and Mark Quade and Brett Terhaar and James Roth and Janice Endsley",
year = "2002",
language = "English (US)",
volume = "3",
journal = "Veterinary therapeutics : research in applied veterinary medicine",
issn = "1528-3593",
publisher = "Veterinary Learning Systems",
number = "4",

}

TY - JOUR

T1 - Bovine viral diarrhea virus type 1 - and type 2-specific bovine T lymphocyte - Subset responses following modified-live virus vaccination

AU - Ripplinger, Kristina

AU - Quade, Mark

AU - Terhaar, Brett

AU - Roth, James

AU - Endsley, Janice

PY - 2002

Y1 - 2002

N2 - Expression of CD25 (interleukin-2 receptor a chain) was used to monitor antigen-specific activation of T lymphocyte subsets (CD4+, CD8 +, and gd T cells) from cattle immunized with modified-live virus (MLV) bovine viral diarrhea virus (BVDV) vaccines. Two groups of 15 animals each were vaccinated with one dose of either BVDV genotype 1 (BVDV-1) or BVDV-1 and BVDV genotype 2 (BVDV-1/2). Six animals negative for both BVDV antibody and BVDV virus were used as negative controls. Three animals vaccinated 7 and 5 weeks before the start of the experiment with MLV BVDV-1 vaccine served as positive controls. Blood samples were taken from the negative control group, the positive control group, and the BVDV-1/2 group 0, 21, 35, 60, and 90 days after vaccination. Blood samples were taken from the BVDV-1 group 0, 21, and 90 days after vaccination. Isolated peripheral blood lymphocytes from immunized and control animals were incubated for 5 days with and without BVDV-1 or BVDV-2. Compared with nonvaccinated animals, a significant (P < .05) increase in expression of CD25 by CD4+ (60 days), CD8+, and gd T (35 to 90 days) lymphocytes from the group given BVDV-1/2 was detected following in vitro exposure to BVDV-1 or BVDV-2 after vaccination. The CD8+ and gd T cells from the group vaccinated with BVDV-1 had significantly (P < .05) increased expression of CD25 compared with nonvaccinates following postvaccination exposure to in vitro BVDV-1 but not to BVDV-2. There was no significant difference between the two vaccinated groups in CD25 expression on any of the T cell subsets in response to BVDV-1 or BVDV-2 exposure. A single administration of MLV BVDV vaccine may be more effective at stimulating CD8+ and gd T cell"specific immune responses to the homologous genotype than to the heterologous genotype.

AB - Expression of CD25 (interleukin-2 receptor a chain) was used to monitor antigen-specific activation of T lymphocyte subsets (CD4+, CD8 +, and gd T cells) from cattle immunized with modified-live virus (MLV) bovine viral diarrhea virus (BVDV) vaccines. Two groups of 15 animals each were vaccinated with one dose of either BVDV genotype 1 (BVDV-1) or BVDV-1 and BVDV genotype 2 (BVDV-1/2). Six animals negative for both BVDV antibody and BVDV virus were used as negative controls. Three animals vaccinated 7 and 5 weeks before the start of the experiment with MLV BVDV-1 vaccine served as positive controls. Blood samples were taken from the negative control group, the positive control group, and the BVDV-1/2 group 0, 21, 35, 60, and 90 days after vaccination. Blood samples were taken from the BVDV-1 group 0, 21, and 90 days after vaccination. Isolated peripheral blood lymphocytes from immunized and control animals were incubated for 5 days with and without BVDV-1 or BVDV-2. Compared with nonvaccinated animals, a significant (P < .05) increase in expression of CD25 by CD4+ (60 days), CD8+, and gd T (35 to 90 days) lymphocytes from the group given BVDV-1/2 was detected following in vitro exposure to BVDV-1 or BVDV-2 after vaccination. The CD8+ and gd T cells from the group vaccinated with BVDV-1 had significantly (P < .05) increased expression of CD25 compared with nonvaccinates following postvaccination exposure to in vitro BVDV-1 but not to BVDV-2. There was no significant difference between the two vaccinated groups in CD25 expression on any of the T cell subsets in response to BVDV-1 or BVDV-2 exposure. A single administration of MLV BVDV vaccine may be more effective at stimulating CD8+ and gd T cell"specific immune responses to the homologous genotype than to the heterologous genotype.

UR - http://www.scopus.com/inward/record.url?scp=79251517771&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79251517771&partnerID=8YFLogxK

M3 - Article

VL - 3

JO - Veterinary therapeutics : research in applied veterinary medicine

JF - Veterinary therapeutics : research in applied veterinary medicine

SN - 1528-3593

IS - 4

ER -